Queenie Fernandes

Ms. Queenie Fernandes


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Afsheen RazaAfsheen Raza
Afsheen Raza
AKAbdul Khan
Abdul Khan
VIVarghese Inchakalody
Varghese Inchakalody
SMSarra Mestiri
Sarra Mestiri
ZYZeenath Safira K. M. Yoosuf
Zeenath Safira K. M. Yoosuf
Said DermimeSaid Dermime
Said Dermime
Colorectal cancer (CRC) is one of the most common cancers worldwide. The diagnosis, prognosis and therapeutic monitoring of CRC depends largely on tissue biopsy. However, due to tumor heterogeneity and limitations such as invasiveness, high cost and limited applicability in longitudinal monitoring, liquid biopsy has gathered immense attention in CRC. Liquid biopsy has several advantages over tissue biopsy including ease of sampling, effective monitoring, and longitudinal assessment of treatment dynamics. Furthermore, the importance of liquid biopsy is signified by approval of several liquid biopsy assays by regulatory bodies indicating the powerful approach of liquid biopsy for comprehensive CRC screening, diagnostic and prognostics. Several liquid biopsy biomarkers such as novel components of the microbiome, non-coding RNAs, extracellular vesicles and circulating tumor DNA are extensively being researched for their role in CRC management. Majority of these components have shown promising results on their clinical application in CRC including early detection, observe tumor heterogeneity for treatment and response, prediction of metastases and relapse and detection of minimal residual disease. Therefore, in this review, we aim to provide updated information on various novel liquid biopsy markers such as a) oral microbiota related bacterial network b) gut microbiome-associated serum metabolites c) PIWI-interacting RNAs (piRNAs), microRNA(miRNAs), Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and d) circulating tumor DNAs (ctDNA) and circulating tumor cells (CTC) for their role in disease diagnosis, prognosis, treatment monitoring and their applicability for personalized management of CRC.

6 July 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
QFQueenie Fernandes
Queenie Fernandes
Maysaloun MerhiMaysaloun Merhi
Maysaloun Merhi
ARAfsheen Raza
Afsheen Raza
VIVarghese Philipose Inchakalody
Varghese Philipose Inchakalody
NANassima Abdelouahab
Nassima Abdelouahab
Said DermimeSaid Dermime
Said Dermime
The role of Epstein–Barr virus (EBV) infection in the development and progression of tumor cells has been described in various cancers. Etiologically, EBV is a causative agent in certain variants of head and neck cancers such as nasopharyngeal cancer. Proteins expressed by the EVB genome are involved in invoking and perpetuating the oncogenic properties of the virus. However, these protein products were also identified as important targets for therapeutic research in the past decades, particularly within the context of immunotherapy. The adoptive transfer of EBV-targeted T-cells as well as the development of EBV vaccines has opened newer lines of research to conceptualize novel therapeutic approaches toward the disease. This review addresses the most important aspects of the association of EBV with head and neck cancers from an immunological perspective. It also aims to highlight the current and future prospects of enhanced EBV-targeted immunotherapies.

20 April 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
QFQueenie Fernandes
Queenie Fernandes
IGIshita Gupta
Ishita Gupta
Semir VranicSemir Vranic
Semir Vranic
Ala-Eddin Al MoustafaAla-Eddin Al Moustafa
Ala-Eddin Al Moustafa
Human papillomaviruses (HPVs) and the Epstein–Barr virus (EBV) are the most common oncoviruses, contributing to approximately 10%–15% of all malignancies. Oncoproteins of high-risk HPVs (E5 and E6/E7), as well as EBV (LMP1, LMP2A and EBNA1), play a principal role in the onset and progression of several human carcinomas, including head and neck, cervical and colorectal. Oncoproteins of high-risk HPVs and EBV can cooperate to initiate and/or enhance epithelial-mesenchymal transition (EMT) events, which represents one of the hallmarks of cancer progression and metastasis. Although the role of these oncoviruses in several cancers is well established, their role in the pathogenesis of colorectal cancer is still nascent. This review presents an overview of the most recent advances related to the presence and role of high-risk HPVs and EBV in colorectal cancer, with an emphasis on their cooperation in colorectal carcinogenesis.

1 May 2017 in Blood Reviews
Verified
Journal Article
Closed access
QFQueenie Fernandes
Queenie Fernandes

1 June 2017 in Life Sciences
Verified
Journal Article
Closed access
QFQueenie Fernandes
Queenie Fernandes

21 July 2021
Verified
Book Chapter
Open access
PDF file
Afsheen RazaAfsheen Raza
Afsheen Raza
Maysaloun MerhiMaysaloun Merhi
Maysaloun Merhi
ARAllan Relecom
Allan Relecom
QFQueenie Fernandes
Queenie Fernandes
VIVarghese Inchakalody
Varghese Inchakalody
Said DermimeSaid Dermime
Said Dermime
Immune checkpoint inhibitors (ICIs) have been approved as first or second line therapy in a large group of cancers. However, the observation of potentially long-lasting responses was restricted to limited subset of patients. Efforts have been made to identify predictive factors of response to ICIs in order to select eligible patients and to avoid exposing non-responding patients to treatment side effects. Although several biomarkers have been identified, their predictive potential remains unsatisfactory. One promising emerging approach is to focus on dynamic biomarkers to directly characterize the response and, more importantly, to identify those patients presenting an immune response failure. Several studies have shown a strong correlation between specific circulating immune cell subsets and tumor immune infiltrates. Moreover, liquid biomarkers including soluble immune checkpoint molecules have potential in predicting the modulation of the immune response under immune checkpoint blockade. In this chapter, we will discuss current advances in the study of circulatory and intra-tumoral dynamic biomarkers as predictors of responses to ICIs therapy in cancer.